Clusterin as a therapeutic target
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Clusterin (CLU) is a stress-activated, ATP-independent molecular chaperone, normally secreted from cells, that is up-regulated in Alzheimer disease and in many cancers. It plays important roles in protein homeostasis/proteostasis, inhibition of cell death pathways, and modulation of pro-survival signalling and transcriptional networks. Changes in the CLU gene locus are highly associated with Alzheimer disease, and many therapy-resistant cancers over-express CLU. The extensive post-translational processing and heterogeneous oligomerization of CLU have so far prevented any definitive structure determination. This in turn has meant that targeting CLU with small molecule inhibitors is challenging. Therefore, inhibiting CLU at the gene-expression level using siRNA or antisense is a valid approach to inhibit its function. Areas covered: This article reviews recent advances regarding the role of CLU in proteostasis, cellular trafficking, human diseases, and signalling pathways involved in oncogenesis. It addresses the rationale for CLU as a therapeutic target in cancer, and the current status of pre-clinical and clinical studies using CLU antisense inhibitor OGX011. Expert opinion: Discusses challenges facing the therapeutic targeting of CLU including rapid changes in the treatment landscape for prostate cancer with multiple new FDA approved drugs, selection of windows of intervention, and potential side effects when silencing CLU expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Second, there has been a rapid change in the treatment landscape for CRPC with multiple new FDA-approved drugs, such as enzalutamide [142] and abiraterone [143], which in phase III clinical trials extended patient survival by over 4 months.”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“1, is homozygously deleted in 20% of CRPC patients [141]; this population of patients is likely to have confounded the evaluation of OGX011.”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Dysfunctions in Aβ clearance are now recognized as of great importance in the development of Alzheimer pathology [85,86] (Figure 2).”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Genome-wide association studies revealed several single nucleotide polymorphisms (SNPs) within the CLU gene (but outside the protein-encoding open reading frame) that are risk factors for AD [71,72].”
BackgroundBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 3×
“ing Aβ from the brain are the bulk flow of interstitial fluid, and receptor-mediated transport involving both lipoproteinrelated protein 1 (LRP1) and LRP2 (megalin) [47].”
BackgroundHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
Jones, S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00155-8 · Cited by 488
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 1×
“disease onset and a marked increase in Aβ peptide levels and amyloid formation [79].”
Clusterin inhibits apoptosis by interacting with activated Bax
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C.-Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1291 · Cited by 453 · cited 2×
“CLU specifically interacts with conformationally altered Bax to inhibit apoptosis in response to chemotherapeutic drugs [38] and CLU knockdown alters”
BackgroundZlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430
DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 1×
“CLU is upregulated in the brain of AD patients compared to controls [74] and is found physically associated with Aβ-rich extracellular plaques [75,76].”
BackgroundBertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00097-c · Cited by 210 · cited 1×
“CLU is upregulated in the brain of AD patients compared to controls [74] and is found physically associated with Aβ-rich extracellular plaques [75,76].”
BackgroundTrougakos, I. P., Lourda, M., Antonelou, M. H., Kletsas, D., Gorgoulis, V. G., Papassideri, I. S., Zou, Y., Margaritis, L. H., Boothman, D. A., & Gonos, E. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1805 · Cited by 160
Clusterin facilitates in vivo clearance of extracellular misfolded proteins
Wyatt, A. R., Yerbury, J. J., Berghofer, P., Greguric, I., Katsifis, A., Dobson, C. M., & Wilson, M. R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0684-8 · Cited by 145
Self-citationLeeb, C., Eresheim, C., & Nimpf, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529271 · Cited by 99 · cited 2×
“The binding of CLU to LRP2 induces activation of AKT and promotes cell survival [108].”
Background
Cited by
Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins
Zeltz, C., Primac, I., Erusappan, P., Alam, J., Noel, A., & Gullberg, D. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.004 · Cited by 290
“Clusterin: Clusterin (CLU) is an ubiquitously expressed heat shock protein and the secreted isoform is highly expressed in mammalian tissues and fluids [96].”
BackgroundOn the origin of proteins in human drusen: The meet, greet and stick hypothesis
Bergen, A. A., Arya, S., Koster, C., Pilgrim, M. G., Wiatrek-Moumoulidis, D., van der Spek, P. J., Hauck, S. M., Boon, C. J. F., Emri, E., Stewart, A. J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.12.003 · Cited by 101
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma
Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U. N., Basu, K., Bota-Rabassedas, N., Guo, H.-F., Grzeskowiak, C. L., Liu, X., Yu, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3772 · Cited by 70
Structural analyses define the molecular basis of clusterin chaperone function
Yuste-Checa, P., Carvajal, A. I., Mi, C., Paatz, S., Hartl, F. U., & Bracher, A. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01631-4 · Cited by 18
Balcar, V. J., Zeman, T., Janout, V., Janoutová, J., Lochman, J., & Šerý, O. (2021) · Neurochemical Research · doi:10.1007/s11064-020-03176-y · Cited by 17
Metadata
- Authors
- Wilson, M. R., & Zoubeidi, A.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2016-12-16
- Volume
- 21
- Issue
- 2
- Pages
- 201-213
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2565780052
- Cited by
- 144
- References
- 19
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.